84 related articles for article (PubMed ID: 11449071)
1. Cytotoxicity of Antiosteosarcoma Recombinant Immunotoxins Composed of TP-3 Fv Fragments and a Truncated Pseudomonas Exotoxin A.
Onda M; Olafsen T; Tsutsumi Y; Bruland ØS ØS; Pastan I
J Immunother (1991); 2001 Mar; 24(2):144-150. PubMed ID: 11449071
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A.
Onda M; Olafsen T; Tsutsumi Y; Bruland OS; Pastan I
J Immunother; 2001; 24(2):144-50. PubMed ID: 11265772
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2.
Bera TK; Viner J; Brinkmann E; Pastan I
Cancer Res; 1999 Aug; 59(16):4018-22. PubMed ID: 10463601
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
6. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
Benhar I; Pastan I
Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
[TBL] [Abstract][Full Text] [Related]
7. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
Reiter Y; Pastan I
Clin Cancer Res; 1996 Feb; 2(2):245-52. PubMed ID: 9816166
[TBL] [Abstract][Full Text] [Related]
8. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
Bera TK; Pastan I
Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.
Onda M; Wang QC; Guo HF; Cheung NK; Pastan I
Cancer Res; 2004 Feb; 64(4):1419-24. PubMed ID: 14973056
[TBL] [Abstract][Full Text] [Related]
10. Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation.
Brinkmann U; Di Carlo A; Vasmatzis G; Kurochkina N; Beers R; Lee B; Pastan I
J Mol Biol; 1997 Apr; 268(1):107-17. PubMed ID: 9149145
[TBL] [Abstract][Full Text] [Related]
11. Purification of clinical-grade disulfide stabilized antibody fragment variable--Pseudomonas exotoxin conjugate (dsFv-PE38) expressed in Escherichia coli.
Jiang H; Xie Y; Burnette A; Roach J; Giardina SL; Hecht TT; Creekmore SP; Mitra G; Zhu J
Appl Microbiol Biotechnol; 2013 Jan; 97(2):621-32. PubMed ID: 22890777
[TBL] [Abstract][Full Text] [Related]
12. A divalent recombinant immunotoxin formed by a disulfide bond between the extension peptide chains.
Park JH; Kwon HW; Chung HK; Kim IH; Ahn K; Choi EJ; Pastan I; Choe M
Mol Cells; 2001 Dec; 12(3):398-402. PubMed ID: 11804341
[TBL] [Abstract][Full Text] [Related]
13. Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice.
Benhar I; Reiter Y; Pai LH; Pastan I
Int J Cancer; 1995 Jul; 62(3):351-5. PubMed ID: 7628878
[TBL] [Abstract][Full Text] [Related]
14. Disulfide bond bridged divalent antibody-toxin, (Fab-PE38fl)2, with the toxin PE38 fused to the light chain.
Won J; Choe M
J Microbiol Biotechnol; 2008 Aug; 18(8):1475-81. PubMed ID: 18756111
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of 111In- and 125I-labeled antiTac single-chain Fv recombinant immunotoxin.
Kobayashi H; Kao CH; Kreitman RJ; Le N; Kim MK; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
J Nucl Med; 2000 Apr; 41(4):755-62. PubMed ID: 10768579
[TBL] [Abstract][Full Text] [Related]
16. Improved stability and yield of Fv targeted superantigen by introducing both linker and disulfide bond into the targeting moiety.
Hao HJ; Jiang YQ; Zheng YL; Ma R; Yu DW
Biochimie; 2005 Aug; 87(8):661-7. PubMed ID: 15927340
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.
Hassan R; Lerner MR; Benbrook D; Lightfoot SA; Brackett DJ; Wang QC; Pastan I
Clin Cancer Res; 2002 Nov; 8(11):3520-6. PubMed ID: 12429643
[TBL] [Abstract][Full Text] [Related]
18. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
19. TP-3 immunotoxins improve antitumor activity in mice with osteosarcoma.
Onda M; Bruland ØS; Pastan I
Clin Orthop Relat Res; 2005 Jan; (430):142-8. PubMed ID: 15662316
[TBL] [Abstract][Full Text] [Related]
20. Technology evaluation: BL22, NCI.
Barth S
Curr Opin Mol Ther; 2002 Feb; 4(1):72-5. PubMed ID: 11883697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
